Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. entered into securities purchase agreements with two accredited investors, issuing $350,000 aggregate principal amount of unsecured promissory notes to raise funds for working capital and other general corporate purposes. The notes bear 6% annual interest and mature one month after issuance, and may be prepaid at any time without penalty.
As an inducement, the investors received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring on the earlier of five years from issuance, a fundamental transaction, or a liquidation event. The securities were issued in a private offering relying on exemptions under Section 4(a)(2) and Rule 506 of Regulation D.
Jaguar Health Chief Scientific Officer Pravin Chaturvedi reported new equity awards in the company’s stock. On December 11, 2025, he received 11,740 restricted stock units, each representing a right to one share of Jaguar Health voting common stock. These restricted stock units vest on December 11, 2026, when the underlying shares are scheduled to be delivered.
On the same date, he was also granted a stock option covering 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, as long as he remains employed, and both awards were granted under Jaguar Health’s 2014 Stock Incentive Plan. Following the grant, he beneficially owned 11,938 shares of common stock directly, plus the 11,740 stock options. The filing also notes a 25-for-1 reverse stock split of Jaguar’s voting common stock effective March 24, 2025.
Jaguar Health director James J. Bochnowski reported new equity awards. On December 11, 2025, he received 6,363 restricted stock units and a stock option for 6,363 shares of common stock, granted under the company’s 2014 Stock Incentive Plan.
Each restricted stock unit represents one share of voting common stock and will vest on December 11, 2026, with shares delivered on that date. The stock option has an exercise price of $1.44 per share, vests ratably on a monthly basis over 12 months from the grant date while he continues serving on the board, and expires on December 11, 2035.
Following the grant, Bochnowski beneficially owned 6,415 shares of Jaguar Health common stock directly.
Jaguar Health director Jonathan B. Siegel reported receiving new equity awards under the company’s 2014 Stock Incentive Plan. The filing shows 7,377 restricted stock units and a stock option covering 7,377 shares of common stock, both granted on 12/11/2025 at no cost for the awards themselves, with the option carrying a $1.44 exercise price and expiring on 12/11/2035.
The restricted stock units are scheduled to vest on 12/11/2026, while the options vest ratably on a monthly basis over 12 months from the grant date, contingent on his continued board service at Jaguar Health and its subsidiary Napo Therapeutics, S.p.A. Following these grants, he directly beneficially owned 7,423 shares of Jaguar Health common stock.
Jaguar Health, Inc. director Anula Jayasuriya received equity awards consisting of 5,870 restricted stock units and stock options covering 5,870 shares of common stock, approved by the board on December 11, 2025 under the company’s 2014 Stock Incentive Plan.
Each restricted stock unit represents a right to receive one share and vests on December 11, 2026, while the options have a $1.44 exercise price, vest monthly over 12 months from the grant date, and expire on December 11, 2035. Following these grants, she beneficially owns 5,916 shares of common stock and 5,870 stock options, held directly.
Jaguar Health, Inc. reported that its Chief Financial Officer, Carol R. Lizak, received new equity awards on December 11, 2025.
The awards include 11,740 restricted stock units, each representing a contingent right to receive one share of voting common stock for $0 consideration, with beneficial ownership of common stock reported as 11,911 shares after the transaction. She also received stock options to purchase 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035.
The grants were made under the company’s 2014 Stock Incentive Plan. The restricted stock units vest on December 11, 2026, and vested shares will be delivered on that vesting date, while the options vest in equal monthly installments over 12 months from the grant date, subject to continued employment.
Jaguar Health, Inc. entered into two privately negotiated exchange agreements with Iliad Research and Trading, L.P., swapping Series M Perpetual Preferred Stock for common stock and pre-funded warrants. On December 9, 2025 the company issued 400,000 common shares and a pre-funded warrant to purchase 1,304,545 common shares in exchange for 75 Series M shares, which were then cancelled and retired. On December 11, 2025 it issued 40,000 common shares and a pre-funded warrant to purchase 304,827 common shares in exchange for 16 additional Series M shares, which were also cancelled and retired. The pre-funded warrants are immediately exercisable at an exercise price of $0.001 per share and include a 9.99% beneficial ownership cap, limiting how much of Jaguar Health’s common stock Iliad and its affiliates may hold after exercise. The securities were issued under the Section 3(a)(9) exemption from Securities Act registration.
Jaguar Health, Inc. is registering up to 2,621,852 shares of common stock for resale by existing investors. These shares include 1,980,827 shares issuable upon exchange of 950.8 outstanding shares of Series N Perpetual Preferred Stock, 161,583 PIPE shares, and 479,442 shares underlying a pre-funded warrant with a $0.0001 exercise price per share. The company will not receive proceeds from stockholder resales and would receive only about $48 if the pre-funded warrant is exercised for cash.
Jaguar is a commercial-stage pharmaceutical company focused on plant-based medicines for gastrointestinal disorders in people and animals. Its lead drug crofelemer underpins approved HIV-related diarrhea treatment Mytesi, a conditionally approved veterinary product for chemotherapy-induced diarrhea in dogs, and multiple late-stage and orphan programs, including cancer therapy-related diarrhea and rare diseases such as short bowel syndrome and microvillus inclusion disease. The company is also expanding into cancer supportive care with Gelclair and exploring CNS indications through its Magdalena joint venture.
Jaguar Health, Inc. entered into new amendments to three existing royalty interest agreements, each with an original principal amount of $12 million. Beginning on April 1, 2026, the monthly royalty payment under each agreement must be the greater of $750,000 or the royalty amount otherwise owed for that month, increasing the company’s fixed payment obligation to its investors Iliad, Uptown, and Streeterville.
Jaguar and its subsidiary Napo Pharmaceuticals also amended a secured promissory note with an original principal amount of $6,220,812.50, extending its maturity date to April 1, 2026, which delays required repayment. In a separate exchange, Jaguar issued 361,271 shares of common stock in a private transaction to Streeterville in exchange for 25 shares of its Series M Preferred Stock, which were then cancelled, simplifying part of its capital structure.